Replies to post #228202 on Biotech Values

[DewDiligence]

PTI—(+11%)—climbs on the COVID-19 bandwagon:

https://www.prnewswire.com/news-releases/proteostasis-therapeutics-announces-in-vitro-data-for-pti-129-as-potential-treatment-candidate-for-covid-19-301068350.html

Proteostasis Therapeutics, a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19. PTI-129 is a pre-clinical, once-daily, oral small molecule originally designed to treat protein misfolding disorders involving the unfolded protein response (UPR).

Caveat emptor.